Specifications
Description | THJ560 Cells are derived from thyroid gland undifferentiated (anaplastic) carcinoma (T4bN1bMx) tissue. The cells are characterized and found to express p53 V274F and BRAF V600E oncogenes, and are tumorigenic in athymic nude mice. |
---|---|
SKU | T8262 |
Species | Human (H. sapiens) |
Tissue/Organ/Organ System | Thyroid |
Donor Gender | Female |
Donor Age | 49 years old |
Donor Disease | Thyroid gland undifferentiated (anaplastic) carcinoma, T4bN1bMx |
Growth Properties | Adherent |
Cell Morphology | Epithelial-like |
Population Doubling Time | 40 hours |
Applications | For Research Use Only |
Unit quantity | 1×106 cells / 1.0 ml |
Cell Type | Tumor Cells |
Propagation Requirements |
Use of PriCoatTM T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) is required for cell adhesion to the culture vessels. Grow cells in ECM-coated culture vessels unless otherwise specified in the Propagation Requirements below. The base medium for this cell line is Prigrow III medium available at abm, Cat. No. TM003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (TM999) to a final concentration of 5%, Penicillin/Streptomycin Solution (G255) to a final concentration of 1%, and HEPES to a final concentration of 10 mM. |
Preservation Protocol | 1. Freeze Medium: Complete growth medium with 20% FBS and 10% DMSO. 2. Storage Temperature: Liquid nitrogen vapour phase. |
QC | 1) STR profiling |
Disclaimer |
|
Depositor | Mayo |
There are no FAQs for this product yet!
5
Hitora, T., Yamamoto, T., Akisue, T., Marui, T., Nakatani, T., Kawamoto, T., … & Kurosaka, M. (2005). Establishment and characterization of a KIT‐positive and stem cell factor‐producing cell line, KTHOS, derived from human osteosarcoma. Pathology international, 55(2), 41-47.
von Roemeling CA, Marlow LA, Pinkerton AB, Crist A, Miller J, Tun HW, Smallridge RC, Copland JA. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target. J Clin Endocrinol Metab. 2015 May;100(5):E697-709. doi: 10.1210/jc.2014-2764. Epub 2015 Feb 12. PMID: 25675381; PMCID: PMC4422887.
Marlow LA, Rohl SD, Miller JL, Knauf JA, Fagin JA, Ryder M, Milosevic D, Netzel BC, Grebe SK, Reddi HV, Smallridge RC, Copland JA. Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3169-3182. doi: 10.1210/jc.2017-01845. PMID: 29846633; PMCID: PMC6126888.
Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin Cancer Res. 2019 May 15;25(10):3141-3151. doi: 10.1158/1078-0432.CCR-18-2953. Epub 2019 Feb 8. PMID: 30737244; PMCID: PMC6522280.